Bormotova E A, Gupalova T V
Klin Lab Diagn. 2016 Aug;61(8):484-9.
The diabetes mellitus and arterial hypertension are among the most significant pathologies conditioning disorder of excretion of protein with urine. These very diseases are mostly dangerous for kidneys. Therefore, important significance has the search of early manifestations of damage of kidneys in patients with these diseases. The microalbuminuria is one of early manifestations of affection of kidneys in patients with diabetes mellitus and arterial hypertension. Only this early (pre-clinical) stage of affection of kidneys is the only reversible one in case of prescription of medicinal therapy. Nowadays, factually all applied diagnostic test-systems for detection ofmicroalbuminuria are based on immunological half-quantitative and quantitative detection of concentration of human serum albumin in urine. In this study was applied new recombinant human serum poly-peptide A3 from strain of streptococcus group G isolated from cow milk. The human serum albumin-binding capacity of poly-peptide A3 was analyzed in comparison with poly-peptide A2. Previously, recombinant human serum albumin-binding poly-peptide A2 was primarily applied in test-system for detection of microalbuminuria instead of commonly used antibodies. The analysis of 'human serum albumin-binding capacity of recombinant human serum poly-peptide A3 and A2 demonstrated that both of them can interact with human serum albumin in solution and adsorbed condition. This characteristic permitted applying poly-peptide A3 in immobilized form in qualitative test-system for detecting microalbuminuria. The actual study also propose specific and sensitive technique of screening and monitoring of patients with diabetes mellitus and arterial hypertension. The mentioned technique used tagged human serum albumin-binding polypeptide A3 combined with microchip technology. The comparison of test-systems using recombinant poly-peptides A3 and A2 established that application of poly-peptide A3 in test-system permits to detect more precisely concentration of human serum albumin in urine samples. The test-system of this kind was successfully implemented for both detection and qualitative identification of microalbuminuria in patients with diabetes mellitus and arterial hypertension.
糖尿病和动脉高血压是导致尿蛋白排泄紊乱的最重要病理状况之一。这些疾病对肾脏危害极大。因此,在这些疾病患者中寻找肾脏损伤的早期表现具有重要意义。微量白蛋白尿是糖尿病和动脉高血压患者肾脏受累的早期表现之一。只有肾脏受累的这个早期(临床前)阶段在进行药物治疗时是唯一可逆转的。如今,实际上所有用于检测微量白蛋白尿的应用诊断测试系统都是基于对尿中人血清白蛋白浓度的免疫半定量和定量检测。在本研究中,应用了从牛奶中分离的G组链球菌菌株的新型重组人血清多肽A3。与多肽A2相比,分析了多肽A3与人血清白蛋白的结合能力。此前,重组人血清白蛋白结合多肽A2主要应用于检测微量白蛋白尿的测试系统中,而非常用抗体。对重组人血清多肽A3和A2与人血清白蛋白结合能力的分析表明,它们在溶液和吸附状态下均能与人血清白蛋白相互作用。这一特性使得多肽A3可以固定化形式应用于检测微量白蛋白尿的定性测试系统中。本实际研究还提出了针对糖尿病和动脉高血压患者的特异性和灵敏的筛查及监测技术。所述技术使用标记的人血清白蛋白结合多肽A3并结合微芯片技术。使用重组多肽A3和A2的测试系统的比较表明,在测试系统中应用多肽A3能够更精确地检测尿样中人血清白蛋白的浓度。这种测试系统已成功用于糖尿病和动脉高血压患者微量白蛋白尿的检测和定性鉴定。